摘要
目的 :探讨全雄激素阻断和全雄激素阻断结合12 5I放射微粒植入治疗前列腺癌的临床疗效。 方法 :收集我院近 10年来中晚期前列腺癌病人 44例 ,其中C期 2 8例 ,D期 16例。双侧睾丸切除 +抗雄激素药物治疗 (A组 )35例 ,双侧睾丸切除 +抗雄激素药物 +12 5I放射微粒植入近距离放射治疗 (B组 ) 9例。比较治疗前后PSA的变化及生存率。 结果 :A组 35例病人PSA平均值由 6 0 .3μg/L降至12 .1μg/L。B组 9例病人PSA平均值由72 .1μg/L降至 3.6 μg/L。 35例A组病人随访 9～ 84(平均39.2 )个月 ,排除非癌性死亡 3例 ,因前列腺癌引起的死亡 6例 ,生存率为 81.3%(2 6 / 32 )。B组 9例病人随访 7～ 2 4(平均 13)个月 ,病人全部存活。 结论 :全雄激素阻断治疗及全雄激素阻断治疗结合12 5I放射微粒植入近距离放射治疗 ,是治疗中晚期前列腺癌的可供选择的有效方法。
Objective: To assess the effect of the maximal androgen blockade( MAB) and MAB combined with 125I brachytherapy on prostatic cancer. Methods: Forty-four patients with prostatic cancer (from 1993 to 2002), 28 at pathologic stage C and 16 at stage D, were analyzed retrospectively. Thirty-five of them were treated by bilateral orchidectomy and anti-androgen drugs, i.e. MAB, and 9 treated by MAB combined with 125I brachytherapy. The survival rates and the variation of serum prostate-specific antigen (PSA) levels between pre- and post-treatment were compared. Results: The level of PSA decreased from 60.3 μg/L to 12.1 μg/L in 35 patients treated by MAB, and from 72.1 μg/L to 3.6 μg/L in 9 patients treated by MAB combined with 125I brachytherapy after 6 months. The post-treatment survival rates were 81.3%(26/32, excluding 3 deaths by other diseases) for patients treated by MAB after a mean follow-up of 39.2(9～84) months and 100% for patients by MAB combined with 125I brachytherapy after a mean follow-up of 13(7～24)months. Conclusion: MAB and MAB combined with 125I brachytherapy are effective for patients with prostatic cancer.
出处
《中华男科学杂志》
CAS
CSCD
2003年第6期434-435,共2页
National Journal of Andrology
